Modification of protein-based drug carriers with tumor-targeting properties is an important area of research in the field of anticancer drug delivery. To this end, we developed nanoparticles comprised of elastin-like polypeptides (ELPs) with fused poly-aspartic acid chains (ELP-D) displaying DNA aptamers. DNA aptamers were enzymatically conjugated to the surface of the nanoparticles via genetic incorporation of Gene A* protein into the sequence of the ELP-D fusion protein. Gene A* protein, derived from bacteriophage ϕX174, can form covalent complexes with single-stranded DNA via the latter's recognition sequence. Gene A* protein-displaying nanoparticles exhibited the ability to deliver the anticancer drug paclitaxel (PTX), whilst retaining activity of the conjugated Gene A* protein. PTX-loaded protein nanoparticles displaying DNA aptamers known to bind to the MUC1 tumor marker resulted in increased cytotoxicity with MCF-7 breast cancer cells compared to PTX-loaded protein nanoparticles without the DNA aptamer modification.
Introduction
Design of drug delivery vehicles is one of the most important areas of research in cancer chemotherapy, with significant efforts directed at avoiding unpleasant or harmful side effects. To date, a variety of nanoparticles have been developed that exhibit the ability to act as drug carriers via passive tumor-targeting associated with enhanced permeability and retention (EPR) effects [1, 2] . Additionally, conjugation of tumor-targeting molecules, such as antibodies, peptides and chemical molecules, to the surface of nanoparticles has been shown to promote active targeting [2, 3] .
Recently, aptamers have attracted attention as potential targeting molecules upon conjugation to nanoparticles [4, 5] . Aptamers are typically single-stranded oligonucleotide ligands for proteins, amino acids, and organic and inorganic compounds. In addition to high binding specificity, aptamers demonstrate advantages over antibodies, such as low molecular weight, simple and reproducible synthesis, ease of modification and low toxicity [5] . A number of DNA aptamers, known to bind to proteins overexpressed in cancer cells, have been conjugated to nanoparticles with demonstrated tumor-active targeting abilities both in vitro and in vivo [6] [7] [8] [9] . Several types of nanoparticles have been employed such as those made from poly (lactic-co-glycolicacid) (PLGA), polysaccharides and proteins.
Protein-based nanoparticles are particularly attractive as potential drug carriers, as they are typically biodegradable, nontoxic, and can be genetically designed. Genetic design of protein-based nanoparticles offers advantages for the construction of anticancer drug carriers, including the ability to display specific tumor-targeting molecules (e.g., proteins and peptides) on their surfaces without chemical modification [10] [11] [12] [13] [14] . Previously, protein-based nanoparticles displaying multivalent epidermal growth factor (EGF) were genetically designed to target tumor cells overexpressing the EGF receptor [15] . These protein nanoparticles were constructed from fusion proteins comprised of elastin-like polypeptides (ELPs) with a fused poly-aspartic acid tail (ELP-D) and 1 3 EGF, and the formation of nanoparticles was due to the balance between the aggregation propensity of ELP and the charge repulsion of the poly-aspartic acid tail. Based on this study, we have recently developed a growth factor-tethered protein nanoparticle system utilizing coiled-coil formation to noncovalently tether growth factors to protein nanoparticles [16] .
In the present study, to expand the applications of our designed protein nanoparticles, DNA aptamer-conjugated modifications were developed. Conjugation of DNA aptamers to nanoparticles is generally accomplished via, for example, crosslinking of the -COOH group on the protein of interest and an -NH 2 group modified at the oligonucleotide terminus [6, 8, 9] . Herein, instead of chemical conjugation, DNA aptamers were enzymatically conjugated to protein nanoparticles through the bacteriophage ϕX174 Gene A* protein. Gene A* protein is the product of internal translation of the Gene A message starting at the 173rd codon, and plays a role in the replication of ϕX174 genome. Gene A* protein retains the activities of DNA strand transfer by cleaving its recognition sequence and covalently attaching to the 5′-phophoryl group of the cleavage site through forming a phosphotyrosine diester [17, 18] . By exploiting this characteristic, we developed a method for site-specific attachment of single-stranded DNA to a recombinant protein of interest creating a Gene A* protein fusion [19, 20] . Here, the gene encoding Gene A* protein was fused to the end of the gene encoding the ELP-D fusion protein. Following expression of the fusion protein and formation nanoparticles displaying the Gene A* protein, DNA aptamers were conjugated to the nanoparticle surface (Fig. 1) . Specifically the DNA aptamer S2.2 was employed, which binds to MUC1, a type I transmembrane glycoprotein overexpressed in various cancer cells [21] . Finally, we evaluated the anticancer effects of paclitaxel-loaded protein nanoparticles displaying MUC1 aptamers on MCF-7 breast cancer cells.
Materials and methods

Materials
Restriction enzymes and ligase were purchased from Takara Bio Inc. (Japan). The sequences of synthetic oligonucleotides including Gene A* recognition sequence (S-ODN) fluorescein isothiocyanate-labeled S-ODN (S-ODN-FITC) MUC1 aptamer S2.2 with Gene A* protein recognition sequence (S-MUC1) and the fluorescein isothiocyanatelabeled S-MUC1 (S-MUC1-FITC) are shown in Table 1 . Human breast cancer cell line, MCF-7 (RBRC-RCB1904), was provided by the RIKEN BRC through the National BioResource Project of MEXT, Japan. All other chemicals were of analytical grade.
Plasmid construction
The plasmid pET28b-(PAVGV) 42 -D 44 -CHis constructed in our previous work [15] was digested with Xho I followed by insertion of the hybridized synthetic DNA oligonucleotides 5′-TCG ACG AAT TCC ATA TGC -3′ and 5′-GCT TAA GGT ATA CGA GCT -3′ containing EcoR I and Nde I restriction enzyme sites. The resulting plasmid was sequenced and digested with EcoR I and Nde I for insertion of the Gene A* protein gene fragment. The Gene A* protein gene fragment was derived from the pET28b-NHis-EGFP-A* plasmid constructed in our laboratory [19] by digestion with EcoR I and Nde I. The resulting plasmid was named pET28b-(PAVGV) 42 -D 44 -A*-CHis.
Expression and purification of fusion proteins
For expression and purification of the fusion protein (PAVGV) 42 ) and re-pelleted by centrifugation at 17,000×g for 30 min at 4 °C. The supernatant was removed and the cell pellet resuspended in 5 mM MgCl 2 and incubated for 10 min on ice followed by centrifugation at 17,000×g for 20 min at 4 °C. After removal of the supernatant, the cell pellet was re-suspended in lysis buffer (50 mM Na 2 HPO 4 , 300 mM NaCl, 10 mM MgCl 2 , 50 mM l-arginine hydrochloride, 10 mM 2-mercaptoethanol, 10% sucrose, 10% glycerol, pH 7.6) and disrupted by sonication. The lysates were centrifuged to remove insoluble cellular debris and the supernatant applied to TALON™ metal affinity resin (Clontech) equilibrated with lysate buffer to purify the proteins by His-tag metal-ion affinity chromatography. After 1 h incubation at 4 °C, the column was washed five times with three column volumes of wash buffer (50 mM Na 2 PHO 4 , 300 mM NaCl, 10 mM 2-mercaptoethanol, 10% sucrose, 5 mM imidazole, pH 8.0). Finally, the same column volume of elution buffer (50 mM Na 2 PHO 4 , 300 mM NaCl, 10 mM 2-mercaptoethanol, 10% sucrose, 200 mM imidazole, pH 7.4) was used to elute the fusion protein. Expression and purification of (PAVGV) 42 -D 44 (ELP-D) was carried out in accordance with our previously published report [15] . Purified ELP-D-A* and ELP-D were dialyzed against phosphate-buffered saline (PBS) using a Slide-A-lyzer dialysis cassette and analyzed by 12% SDS-PAGE. Concentrations of the purified proteins were determined with the BCA assay kit.
Evaluation of Gene A* protein activity
Purified ELP-D-A* (5 µM) was mixed with the fluorescently modified single-stranded DNA, S-ODN-FITC, in PBS containing MgCl 2 (5 mM). After incubation for 30 min at 37 °C, the samples were analysed by 12% SDS-PAGE and visualized using a fluorescence scanner to confirm the activity of Gene A* protein.
Thermal characterization
The transition temperatures of the purified proteins were evaluated by measuring the turbidity at 350 nm in a UV-vis spectrometer (DU-7500, Beckman Coulter). Purified proteins, filtered through a 0.22-µm filter, were dissolved in PBS (pH 7.4) to a final concentration of 0.2 mg/ml. The samples were heated from 20 to 50 °C, and subsequently cooled back to 20 °C at a rate of 1 °C/min.
Dynamic light scattering (DLS)
Dynamic light scattering data were obtained with a Nano-ZS (Sysmex). Purified proteins, filtered through a 0.22-µm filter, were dissolved in PBS (pH 7.4) to a final concentration of 0.2 mg/ml. Samples were equilibrated at the measuring temperature (20 °C, 37 °C and 20 °C, cooled following incubation at 37 °C) for 10 min prior to data collection. Light scattering data at 90° and 633 nm were collected for at least 10 s × 10 runs. The sizes of the proteins were calculated based on the assumption that the viscosity of PBS was the same as that of water. The particle size with a single-peak distribution was calculated by the Cumulant method. Conversion from an intensity distribution to a volume distribution was performed with the Nano-ZS instrument software.
Evaluation of fluorochrome-loaded protein nanoparticles
Equal volumes of ELP-D and ELP-D-A* (both at a concentration of 0.2 mg/ml) were mixed with 100 µM 1-anilinonaphthalene-8-sulfonic acid (1,8-ANS) in PBS followed by incubation at 25 °C for 10 min. Emission spectra (370 nm excitation) at 25 °C were measured three times at using a FP-6500 spectrofluorometer (JASCO, Japan). The samples were then incubated for 10 min at 37 °C, and the emission spectra (370 nm excitation) were again measured three times.
Formation of paclitaxel-loaded protein nanoparticles with DNA aptamer surface modification
Equal volumes of ELP-D and ELP-D-A* (0.2 mg/ml each) were mixed with either paclitaxel (PTX) (10 µM) or paclitaxel conjugated with Oregon Green 488 (PTX488: Molecular Probes) (1 µM) in PBS followed by incubation at 37 °C for 10 min. DNA aptamer (S-MUC1 or S-ODN) was then added to the mixture, which was subsequently allowed to incubate at 37 °C for 30 min in the presence of 5 mM Mg 2+ . Following incubation, PTX-loaded protein nanoparticles were dialyzed against PBS at 37 °C.
Cellular binding of protein nanoparticles with DNA aptamer surface modification
MCF-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% (v/v) fetal bovine serum (FBS) and antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin). After the maintenance culture, MCF-7 cells were seeded in 35-mm glass bottom dishes (IWAKI) at a density of 1 × 10 4 cells/well. After 1 day of culture, the medium was replaced with a serum-free medium. After incubation for another day, protein nanoparticles loaded with PTX488 carrying DNA on their surface were added and the cells were then allowed to incubate for 3 h prior to observation via laser scanning microscopy (FV-300; OLYMPUS, Japan).
In vitro cytotoxicity
MCF-7 cells were seeded into a 96-well plate at a density of 5 × 10 4 cells/well. After 1 day of culture, the medium was replaced with a serum-free medium. After incubation for another day, protein nanoparticles loaded with PTX and carrying a DNA aptamer surface modification were added to the cells. After culturing the cells they were stained with calcein-AM (Dojindo, Japan) and propidium iodide (PI) to assess cell viability.
Results and discussion
Expression of fusion proteins and activity of Gene A* protein
Our designed protein nanoparticles comprised ELP repeats fused to a poly-aspartic acid chain that allowed for regulation of particle size by charge repulsion [15] . Bacteriophage ϕX174 Gene A* protein was genetically introduced into the sequence of the nanoparticle-forming protein to allow for the display of DNA aptamers on the surface of the nanoparticles for active tumor targeting. In the presence of divalent metal ions, both Gene A* protein and its fusion proteins are known to form covalent complexes with single-stranded DNA via a recognition sequences in vitro [17] [18] [19] [20] . Therefore, Gene A* protein genetically fused to the C-terminus of ELP-D allowed enzymatic conjugation of DNA aptamers. The plasmid, pET28b-(PAVGV) 42 -D 44 -A*-CHis, was transfected into BLR(DE3) competent E. coli cells, and the expressed fusion protein ELP-D-A* (Fig. 2a) . The protein was purified from the soluble fraction and analyzed by SDS-PAGE. The bands of ELP-fused proteins often appear larger than the expected molecular mass due to the physicochemical characteristics of ELPs [22] . However, the ELP-D-A* band appeared at nearly the expected molecular mass (66.1 kDa) as shown in Fig. 2b lane 1 . Since the molecular mass of Gene A* protein (38.7 kDa) is larger than that of ELP-D (26.7 kDa), it is therefore suggested that the physicochemical characteristics of the ELPs did not affect the SDS-PAGE results in this instance.
To test whether Gene A* protein fused to ELP-D retained its activity and could covalently conjugate DNA, FITCmodified single-stranded DNA containing a Gene A* protein recognition sequence, S-ODN-FITC, was added to the fusion protein. Following incubation at 37 °C for 30 min in the presence of 5 mM MgCl 2 , samples were separated by SDS-PAGE and analyzed using a fluorescence scanner. In the presence of S-ODN-FITC, an additional band at higher molecular weight was observed, as shown in Fig. 2b . Moreover, the ELP-D-A* band decreased in intensity as the concentration of DNA was increased. Several weak bands, besides ELP-D-A*, were not disappeared and shifted even after addition of S-ODN-FITC, therefore they would be contaminants. Fluorescence imaging of the gels confirmed the (Fig. 2c) , and so demonstrating that Gene A* protein indeed retains its activity following fusion with ELP-D. Moreover, even in the presence of contaminants, ELP-D-A* showed Gene A* protein activity.
Thermoresponsive protein nanoparticle formation
ELP-D has previously been shown to form nanoparticles following incubation above the thermal transition temperature [15] . To test whether ELP-D-A* could also form protein nanoparticles, the thermal transition temperatures of both ELP-D-A* and ELP-D were evaluated. Thermal transition temperatures were determined by monitoring the optical density at 350 nm while the aqueous solution was heated from 20 to 50 °C, and subsequently cooled back to 20 °C. The turbidity profile of ELP-D-A* was nearly identical to that of ELP-D (Fig. 3) , with a midpoint around 33 °C. Fusion proteins were therefore incubated at 37 °C to allow for nanoparticle formation. Upon cooling from 50 to 20 °C, thermal transitions were not observed for either of the proteins.
Particle sizes were evaluated by DLS. The size distributions of ELP-D and ELP-D-A* were measured at 20 °C, 37 °C and then again at 20 °C, after being cooled from 37 °C (Fig. 4a, b) . At 20 °C, the sizes of ELP-D and ELP-D-A* were found to be ~ 8 nm and ~ 20 nm, respectively, which reflects their respective molecular masses. As previously mentioned, the molecular mass of ELP-D-A* (66.1 kDa) is larger than that of ELP-D (26.7 kDa). At 37 °C, above the transition temperature, the size of ELP-D increased to ~ 30 nm, and is indicative of particle formation. However, the size of ELP-D-A* increased to ~ 1 µm, suggesting formation of ELP-D-A* aggregates, rather than protein nanoparticles, most likely due to steric hindrance introduced upon incorporation of Gene A* protein. While ELP-D fused with EGF was shown to form protein nanoparticles [15] , the mass of Gene A* protein is about five times larger than that of EGF. This difference may account for the difference in forming protein nanoparticles. Another possibility is the potential interaction of Gene A* protein with the poly-aspartic acid chain, as the pI of Gene A* protein is ~ 10.4, and is therefore positively charged in PBS solution and this interaction would reduce the charge repulsions between the poly(aspartate) regions. To mitigate the potential effects of Gene A* protein and promote nanoparticle formation, we combined ELP-D and ELP-D-A*. Equal weights of both proteins were mixed and the particle sizes were evaluated by DLS (Fig. 4c) . Due to the differences in molecular weight between the two proteins, the number of ELP-D molecules in the mixture was 2.5 times larger than that of ELP-D-A*. At 20 °C, the size distribution of the proteins was ~ 10 nm, which is between of the size distributions observed for ELP-D and ELP-D-A* individually. At 37 °C, above the transition temperature, the protein sizes were distributed around 30 nm, which is similar to the distribution observed for ELP-D, and significantly smaller than that observed for ELP-D-A* alone. These results suggest that ELP-D-A* proteins were incorporated into nanoparticles formed by ELP-D and Gene A* proteindisplaying nanoparticles could be formed above the transi- ELP-D-A* could be formed. Meanwhile, protein nanoparticles with conjugated S-MUC1 showed additional bands, at higher molecular weights. These bands appeared at the same size as S-MUC1-conjugated ELP-D-A* (data not shown), and suggest that the MUC1 aptamer containing the Gene A* protein recognition sequence was indeed conjugated to ELP-D-A*, even after formation of protein nanoparticles.
Further, the size of DNA-displaying nanoparticles was nearly the same as protein nanoparticles without DNA conjugation (Fig. 6 ). The observed sizes should reflect the amount of DNA displayed on the surface of the nanoparticles. It suggested that the efficiency of DNA conjugation to Gene A* protein-displaying nanoparticles was lower than that of ELP-D-A* without protein nanoparticle formation. This may be caused by charge repulsion between DNA and the surfaces of the protein nanoparticles.
Binding ability of S-MUC1-displaying nanoparticles to MCF-7 cell lines
S-MUC1 is known to specifically bind to the MUC1 protein [21] so the binding ability of S-MUC1-displaying protein nanoparticles to MCF-7 cells was investigated. MCF-7 is a human breast cancer cell line that overexpresses the MUC1 protein on its surface and the interaction with the MUC1 aptamer has been well-studied [6, 23] . Our ELPbased protein nanoparticles exhibit the ability to take up hydrophobic drugs owing to their non-polar core, which is comprised of ELP aggregates [15] . To confirm the ability of Gene A* protein-displaying nanoparticle to take in hydrophobic drugs, 1-anilino-8-naphthalene sulfonic acid (1,8-ANS), a well-known fluorescent probe used for the analysis of microscopic environment, polarity and hydrophobicity, as a model system of a hydrophobic drug was loaded into the nanoparticles. As shown in Fig. 7 , Gene A* protein-displaying nanoparticles could take in 1,8-ANS to an extent similar to that observed for nanoparticles formed by ELP-D alone. From these results, Gene A* protein-displaying nanoparticle also has an ability to take in hydrophobic drugs as same as nanoparticles formed by ELP-D alone. Therefore, PTX conjugated with Oregon Green 488 (PTX488) was introduced into protein nanoparticles to allow for their visualization.
After formation of the PTX488-loaded protein nanoparticles, S-MUC1 was displayed on the surface via conjugation to Gene A* protein. For formation of the PTX488-loaded protein nanoparticles, 1 µM PTX488 was added to protein mixture. After removal of un-incorporated PTX488 and unreacted S-MUC1 by dialysis, the fluorescent signal derived from PTX488 were kept around 100% compared to PTX488 solution (data not shown). Then, the protein nanoparticles were added to living cells in the absence of FBS and incubated for 3 h. As shown in Fig. 8 , cells incubated with ODN-displaying protein nanoparticles did not show fluorescence. On the other hand, cells incubated with nanoparticles displaying S-MUC1showed a fluorescence signal attributed to PTX488 within the protein nanoparticles. These results demonstrate that S-MUC1 was displayed on the surface of protein nanoparticles via conjugation to Gene A* protein and imparted active targeting properties to them.
Induction of cell death by PTX-loaded protein nanoparticles displaying S-MUC1
To evaluate the ability of PTX-loaded protein nanoparticles displaying S-MUC1 (MUC1-NPs) to induce cell death, live/dead cell staining with calcein-AM and PI, respectively was used. In here, for formation of PTX-loaded protein nanoparticles, 10 µM PTX was added to protein mixture. In case of PTX488, the drug loading efficiency at 10 µM of PTX488 was around 15% (data not shown).
Therefore, it was suggested almost same amount of PTX was incorporated into protein nanoparticles. After 1 day of culture there was little cell death with either PTX or PTX loaded protein nanoparticles (Fig. 9) ; However, after 3 days there is clearly a cytotoxic effect seen with both PTX and PTX-loaded protein nanoparticles displaying S-MUC1. The results for the PTX loaded nanoparticles displaying ODN on their surface showed much less cytotoxicity. It is known that MUC1 is endocytosed to recycle through the trans-Golgi network [24] . Hisatsune et al. reported that antibody-induced internalization of MUC1 involves the macropinocytotic pathway [25] . Moreover, several studies have demonstrated internalization of S-MUC1-conjugated protein nanoparticles. Therefore, it is suggested that our S-MUC1-displaying protein nanoparticles were also internalized into cells and released PTX following their degradation.
Conclusions
In this study, DNA aptamer-displaying protein nanoparticles were developed for use as targeted drug delivery systems. To allow for conjugation of DNA aptamers on the exterior of the protein nanoparticles, Gene A* protein was genetically introduced to an ELP fusion protein containing a polyaspartic acid chain. Although this fusion protein was not able to form protein nanoparticles independently, combination with the non-Gene A* protein-displaying ELP fusion protein allowed for nanoparticle formation. The resultant protein nanoparticles were enzymatically conjugated with DNA aptamers via Gene A* protein and demonstrated active targeting abilities. Our strategy should contribute to expanding the utilities of protein nanoparticles. 
